Instructions for IRS-19 spray
The drug IRS 19 is an immunostimulating agent, has a bacterial origin.
IRS-19 Pharmacological properties:
IRS 19 is used in local treatment of inflammatory diseases of the upper and lower respiratory tract in acute and chronic forms. Also, the drug can be prescribed as a preventive measure for recurrent bronchitis and chronic diseases of the nasopharynx and paranasal sinuses, as well as to strengthen local immunity.
The active ingredient is lysates (individual elements) of bacteria, which most often contribute to the onset of inflammatory processes in the respiratory organs. In addition, the composition of the spray IRS 19 includes excipients, which, in combination with active ingredients, provide an effective increase in local immunity through the formation of antibodies on the surface of the mucous membrane both in the nasopharynx and larynx, and in the alveoli and bronchi of various sizes. Due to an increase in the content of lysozyme and phagocytic activation of macrophages, the use of the drug strengthens the nonspecific immunity of the body.
IRS-19 Indications for use:
IRS 19 is used for the prevention and treatment of inflammatory and / or infectious diseases of the upper respiratory tract:
rhinitis (inflammation of the nasal mucosa),
pharyngitis (inflammation of the pharynx), laryngitis (inflammation of the larynx),
tonsillitis (inflammation of the tonsils - tonsils), otitis media (inflammation of the cavity ear)
infectious-allergic bronchial asthma;
complications of influenza and other viral infections.
For premedication (preparation for surgery) and postmedication (relief after surgery) during surgical interventions on the ENT organs.
IRS-19 Mode of application:
In acute diseases, 2-4 injections of IRS 19 aerosol into each nasal passage per day until the symptoms of the disease disappear (8-10 days).
For chronic diseases and for prophylaxis, two injections per day for 4 weeks are sufficient.
Contraindications:
Contraindications to the use of IRS 19 are: autoimmune diseases; hypersensitivity to the components of the drug.
Pregnancy
There is insufficient data on the potential for teratogenic or toxic effects on the fetus during pregnancy. Therefore, the use of IRS 19 during pregnancy is not recommended.
Interaction with other medicinal products
Cases of negative interaction of IRS 19 with other drugs are unknown.
In the event of the appearance of clinical symptoms of a bacterial infection, antibiotics may be prescribed against the background of the continued use of IRS 19 .
Side effects:
At the beginning of treatment, rhino-rhea (runny nose) is possible, which indicates good organic stimulation.
Overdose:
Overdose cases of IRS 19 are unknown.
Storage conditions
Store IRS 19 away from fire and sources of high temperature.
Release form:
Aerosol vials with 20 ml of solution (60 doses) containing: standardized lysate (decay product) of Diplococcus pneumoniae bacteria - 1.32 ml,
Haemophilus influenzae - 0.66 ml,
Streptococcus pyogenes and S. faecalis - 1.32 ml,
Staphylococcus aureus - 1.32 ml,
KJebsiella pneumoniae - 1.32 ml,
Neisseria catharhalis, flava and perflava - 1.32 ml,
Gafkya tetragena - 0.66 ml,
Ma-raxella - 0.66 ml.
